๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chemotherapy
Clinical trial register · China

Chemotherapy Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 10 Beijing 5 Shanghai 5 Xining 3 Shaoguan 3
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University9 Fudan University3 Zibo Municipal Hospital2 Affiliated Hospital of Qinghai University2 Tang-Du Hospital2
Site location
Guangzhou10 Beijing5 Shanghai5 Xining3 Shaoguan3
All 25 locations
Target enrolment
to

Chemotherapy trials in China

40 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Advanced Cancer
NCT07644533Electroacupuncture, Chemotherapy, Advanced Cancer, Peripheral Neuropathy
Affiliated Hospital of Qinghai University
Not applicable
264
Xining
2026-05-25
Not yet open
Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Early-stage Cancer
NCT07663396Electroacupuncture, Chemotherapy, Peripheral Neuropathy, Early Stage Cancer
Affiliated Hospital of Qinghai University
Not applicable
278
Xining
2026-05-25
Not yet open
Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC
NCT07561983Unresectable Stage III Non-small Cell Lung Cancer, Tislelizumab, Chemotherapy, Chemoembolization, Therapeutic
Sichuan Cancer Hospital and Research Institute
Phase 2
39
Chengdu
2026-05-01
Not yet open
Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2
NCT07531979ESCC, Tislelizumab, Chemotherapy, Becotatug Vedotin
Tianjin Medical University Cancer Institute and Hospital
Phase 2
93
Tianjin
2026-04-01
Recruiting
A Pilot Study Evaluating ฮฒ-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer
NCT07239466Rectal Cancer, Radiotherapy, Immunotherapy, Chemotherapy
Tao Zhang
Phase 2
25
Wuhan
2026-01-01
Not yet open
Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer
NCT07261592Bladder Cancer, Histone Deacetylase Inhibitor, Entinostat, Chemotherapy
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1/2
29
Nanjing
2025-12-01
Recruiting
Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma
NCT07072351Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy, Immunotherapy, Chemotherapy
West China Hospital
Phase 1/2
88
Xiamen, Chengdu
2025-09-15
Recruiting
Clinical Study of Acupoint Application on Relieving qi Deficiency and Constipation in Patients Undergoing Chemotherapy
NCT07276932Postoperative Chemotherapy, Chemotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
106
Hangzhou
2025-07-16
Recruiting
Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
NCT06896422Non-Small Cell Lung Cancer, Chemotherapy, PD1 Antibody, Glutathione
The First Affiliated Hospital of Zhengzhou University
Phase 1
80
Zhengzhou
2025-06-01
Recruiting
A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer
NCT07562490ctDNA, Chemotherapy, Colorectal Cancer
Fudan University
Phase 2
100
Shanghai
2025-04-01
Recruiting
Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
NCT06768307SCLC, Extensive Stage, Immunotherapy, Chemotherapy, Radiotherapy
Peking University Cancer Hospital & Institute
Phase 2
60
Beijing
2025-01-07
Recruiting
Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
NCT06764680Colorectal Cancer Metastatic, Chemotherapy, Targeted Therapy, Immunotherapy
Sun Yat-sen University
Phase 2
57
Guangzhou
2024-12-31
Recruiting
Application of MRI Radiomics Features in Neoadjuvant Therapy of Head and Neck Squamous Cell Carcinoma
NCT06755567Head and Neck Cancer, Neoadjuvant Therapy, Immunotherapy, Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
750
Guangzhou
2024-12-25
Not yet open
BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients
NCT06673459T-Cell Lymphocytic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Total Body Irradiation, Chemotherapy
The First Affiliated Hospital of Soochow University
Phase 3
430
Suzhou
2024-12-01
Recruiting
Effect of Vitamin D Supplementation on Chemotherapy Side Effects After Adjuvant Chemotherapy for Breast Cancer
NCT06642441Vitamin D, Chemotherapy, Breast Cancer, Adverse Reaction
Jiuda Zhao
Not applicable
100
Xining
2024-12-01
Not yet open
Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment
NCT06662877Biliary Tract Cancer, Second Line Treatment, Chemotherapy, Tyrosine Kinase Inhibitor
Sun Yat-sen University
Phase 2/3
206
Guangzhou
2024-11-25
By invitation
IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma
NCT06688175Nasopharyngeal Neoplasms, Elderly, Chemotherapy
The First Affiliated Hospital of Xiamen University
Phase 2
32
Xiamen
2024-11-13
Recruiting
Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer
NCT07562711ctDNA, Chemotherapy, Colorectal Cancer
Fudan University
Phase 2
340
Shanghai
2024-11-01
Recruiting
Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer
NCT07562503ctDNA, Colorectal Cancer, Chemotherapy
Fudan University
Phase 2
340
Shanghai
2024-11-01
Recruiting
A Stuty on the Treatment and Nursing Care of CIPN Patients With Traditional Chinese Medicine Hot Package
NCT06492083Chemotherapy
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Not applicable
90
Yiwu
2024-10-30
Recruiting
dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma
NCT06609863Advanced Hepatocellular Carcinoma, Atezolizumab, Bevacizumab, Chemotherapy
Sun Yat-sen University
Not applicable
27
Beijing
2024-10-01
Recruiting
Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer๏ผšA Prospective, Single-Arm, Phase II Study
NCT07085182NSCLC, Tislelizumab, Chemotherapy, Hypofractionated Radiotherapy
Zibo Municipal Hospital
Phase 2
20
Zibo
2024-01-13
Recruiting
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
NCT05941741Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy, Chemotherapy
Sun Yat-sen University
Phase 3
380
Guangzhou, Nanning, Nanchang
2024-01-10
Recruiting
Correlation of Timing of Pegfilgrastim Administration and PIBP.
NCT05841186Pegfilgrastim, Bone Pain, Chemotherapy, Breast Cancer
Guangdong Provincial People's Hospital
Not applicable
156
Guangzhou
2023-05-04
Recruiting
Adjuvant Chemotherapy Combined With Camrelizumab for โ…กA -โ…ขA NSCLC Patients
NCT05825443Immunotherapy, Chemotherapy
Nanfang Hospital, Southern Medical University
Phase 2
57
Guandong
2023-04-10
Not yet open
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC
NCT05780294Nasopharyngeal Carcinoma, Leucogen, Chemotherapy, Myelosuppression
Sun Yat-sen University
Phase 3
132
Guangzhou
2023-04-01
Recruiting
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
NCT06410651Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
53
Beijing
2023-03-01
Recruiting
Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
NCT06429839Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
55
Beijing
2023-03-01
Active, closed
Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)
NCT05621707Esophageal Squamous Cell Carcinomas, Concurrent Chemoradiotherapy, Immunotherapy, Chemotherapy
Shanghai Chest Hospital
Phase 2
50
Shanghai
2022-11-02
Recruiting
Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell
NCT06006650Neoadjuvent, PD-1 Inhibitor, Chemotherapy, Esophageal Squamous Cell Carcinoma
Tang-Du Hospital
Phase 2
114
Xi'an, Xiโ€™an
2022-08-01
Recruiting
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
NCT05125055Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1, Chemotherapy
Shanghai Jiao Tong University School of Medicine
Phase 2/3
80
Shanghai
2021-10-01
Not yet open
An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC
NCT04890522Nasopharyngeal Carcinoma, Metastasis, Chemotherapy, Immunotherapy
Sun Yat-sen University
Phase 2/3
622
Guangzhou
2021-07-01
Recruiting
Toripalimab Plus FLOT in Locally Advanced Gastric Cancer
NCT04891016Chemotherapy, Immune Checkpoint Inhibitor, Locally Advanced Gastric Carcinoma
Henan Cancer Hospital
Phase 2
60
Zhengzhou
2021-06-25
Recruiting
Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient
NCT07198217NSCLC, Tislelizumab, Chemotherapy, Hypofractionated Radiotherapy
Zibo Municipal Hospital
Phase 2
20
Zibo
2021-05-25
Active, closed
Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC
NCT05400070Sintilimab, Lung Cancer, Anlotinib, Chemotherapy
Tang-Du Hospital
Phase 2
45
Xi'an
2021-03-01
Recruiting
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
NCT04453826Nasopharyngeal Cancer, Chemotherapy, Radiotherapy, PD-1 Therapy
Sun Yat-sen University
Phase 3
388
Guangzhou, Shaoguan, Zhongshan, Zhuhai, Wuzhou
2020-09-01
Recruiting
Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma
NCT04448522Nasopharyngeal Carcinoma, Radiotherapy, Chemotherapy
Sun Yat-sen University
Phase 3
508
Guangzhou, Shaoguan, Zhongshan, Wuzhou
2020-08-18
Recruiting
Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
NCT04453813Nasopharyngeal Carcinoma, Chemotherapy, Radiotherapy, PD-1 Treatment
Sun Yat-sen University
Phase 3
226
Guangzhou, Shaoguan, Zhongshan, Zhuhai, Wuzhou
2020-07-03
Recruiting
Adjuvant Chemotherapy for High Malignant Prostate Cancer
NCT06864533Prostate Cancer, Radiation Therapy, Chemotherapy, Gleason Score
Peking University First Hospital
Observational
315
Beijing, Shenzhen, Baoding
2019-09-01
Recruiting
Colorectal Cancer Dataset in Xijing Hospital From 2011
NCT06308354Prognostic Cancer Model, Chemotherapy, Nutrition Related Cancer
Xijing Hospital
Observational
40,000
Xi'an
2011-01-01
Rows per page Showing 1–40 of 40
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/condition/chemotherapy

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 40 of those studies listing the condition Chemotherapy.

How many Chemotherapy trials are recruiting in China?

28 of the 40 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 9 have not yet opened recruitment, 2 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Chemotherapy), 40 studies
PhaseStudiesRecruitingShare
Phase 2181345%
Not applicable7517.5%
Phase 36415%
Observational337.5%
Phase 2/3317.5%
Phase 1/2215%
Phase 1112.5%

Most active sponsors

Lead sponsors with the most studies (Chemotherapy)
Lead sponsorStudiesRecruiting
Sun Yat-sen University96
Fudan University33
Affiliated Hospital of Qinghai University20
Cancer Institute and Hospital, Chinese Academy of Medical Sciences22
Tang-Du Hospital21
Zibo Municipal Hospital22
Guangdong Provincial People's Hospital11
Henan Cancer Hospital11
Jiuda Zhao11
Nanfang Hospital, Southern Medical University11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.